Compare CION & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CION | AVXL |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 496.0M | 397.6M |
| IPO Year | N/A | N/A |
| Metric | CION | AVXL |
|---|---|---|
| Price | $9.47 | $5.01 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.50 | ★ $22.00 |
| AVG Volume (30 Days) | 442.0K | ★ 2.0M |
| Earning Date | 11-06-2025 | 02-11-2026 |
| Dividend Yield | ★ 12.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $244,923,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.51 | $2.86 |
| 52 Week High | $12.71 | $13.99 |
| Indicator | CION | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 67.85 |
| Support Level | $9.30 | $4.67 |
| Resistance Level | $9.74 | $4.44 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 26.90 | 89.40 |
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.